Pim1 inhibition as a novel therapeutic strategy for Alzheimer’s disease

[1]  Dongke Wu,et al.  Investigation of PI3K/PKB/mTOR/S6K1 signaling pathway in relationship of type 2 diabetes and Alzheimer's disease. , 2015, International Journal of Clinical and Experimental Medicine.

[2]  J. Talboom,et al.  The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease , 2015, npj Aging and Mechanisms of Disease.

[3]  A. Messina,et al.  Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease , 2015, The Journal of Neuroscience.

[4]  A. Richardson,et al.  How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story , 2015, Experimental Gerontology.

[5]  A. Dillin,et al.  The role of protein clearance mechanisms in organismal ageing and age-related diseases , 2014, Nature Communications.

[6]  A. Messina,et al.  Genetic Reduction of Mammalian Target of Rapamycin Ameliorates Alzheimer's Disease-Like Cognitive and Pathological Deficits by Restoring Hippocampal Gene Expression Signature , 2014, The Journal of Neuroscience.

[7]  A. Schürmann,et al.  Over-expression of PRAS40 enhances insulin sensitivity in skeletal muscle , 2014, Archives of physiology and biochemistry.

[8]  E. Cohen,et al.  Selective manipulation of aging: a novel strategy for the treatment of neurodegenerative disorders. , 2014, Swiss medical weekly.

[9]  Han-Chang Huang,et al.  Relationship between amyloid-beta and the ubiquitin–proteasome system in Alzheimer’s disease , 2014, Neurological research.

[10]  S. C. Penley,et al.  Use of an eight-arm radial water maze to assess working and reference memory following neonatal brain injury. , 2013, Journal of visualized experiments : JoVE.

[11]  Sharon C. Yates,et al.  Dysfunction of the mTOR pathway is a risk factor for Alzheimer’s disease , 2013, Acta neuropathologica communications.

[12]  S. Lehr,et al.  Knockdown of PRAS40 inhibits insulin action via proteasome-mediated degradation of IRS1 in primary human skeletal muscle cells , 2013, Diabetologia.

[13]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[14]  P. Rabinovitch,et al.  mTOR is a key modulator of ageing and age-related disease , 2013, Nature.

[15]  U. Hille,et al.  Lymphedema of the breast as a symptom of internal diseases or side effect of mTor inhibitors. , 2012, Lymphatic research and biology.

[16]  A. Ersoy,et al.  Everolimus-induced lymphedema in a renal transplant recipient: a case report. , 2012, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[17]  Smita Majumder,et al.  Inducing Autophagy by Rapamycin Before, but Not After, the Formation of Plaques and Tangles Ameliorates Cognitive Deficits , 2011, Alzheimer's & Dementia.

[18]  Hao Jiang,et al.  Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. , 2012, Cellular signalling.

[19]  M. Lacouture,et al.  Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. , 2012, The oncologist.

[20]  H. A. van den Berg,et al.  Interaction of fast and slow dynamics in endocrine control systems with an application to β-cell dynamics. , 2012, Mathematical biosciences.

[21]  J. Kumar,et al.  Activation of a non-genomic Pim-1/Bad-Pser75 module is required for an efficient pro-survival effect of Bcl-xL induced by androgen in LNCaP cells. , 2011, The international journal of biochemistry & cell biology.

[22]  A. Caccamo,et al.  Methylene Blue Reduces Aβ Levels and Rescues Early Cognitive Deficit by Increasing Proteasome Activity , 2011, Brain pathology.

[23]  A. Caccamo,et al.  Naturally Secreted Amyloid-β Increases Mammalian Target of Rapamycin (mTOR) Activity via a PRAS40-mediated Mechanism* , 2011, The Journal of Biological Chemistry.

[24]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[25]  F. Das,et al.  PRAS40 acts as a nodal regulator of high glucose‐induced TORC1 activation in glomerular mesangial cell hypertrophy , 2010, Journal of cellular physiology.

[26]  Arlan Richardson,et al.  Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. , 2010, The Journal of biological chemistry.

[27]  Jayanta Debnath,et al.  Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease , 2010, PloS one.

[28]  A. Kraft,et al.  PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells , 2009, Cancer biology & therapy.

[29]  F. LaFerla,et al.  Aβ inhibits the proteasome and enhances amyloid and tau accumulation , 2008, Neurobiology of Aging.

[30]  S. Oddo,et al.  The ubiquitin-proteasome system in Alzheimer's disease , 2008, Journal of cellular and molecular medicine.

[31]  D. Connor,et al.  The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007 , 2007, Cell and Tissue Banking.

[32]  B. Winblad,et al.  p70 S6 kinase and tau in Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[33]  R. Roth,et al.  PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding* , 2007, Journal of Biological Chemistry.

[34]  S. Carr,et al.  PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. , 2007, Molecular cell.

[35]  Timothy J. Griffin,et al.  Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 , 2007, Nature Cell Biology.

[36]  J. Eckel,et al.  Insulin-Mediated Phosphorylation of the Proline-Rich Akt Substrate PRAS40 Is Impaired in Insulin Target Tissues of High-Fat Diet–Fed Rats , 2006, Diabetes.

[37]  D. Diamond,et al.  Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice , 2006, Nature Protocols.

[38]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[39]  B. Winblad,et al.  [Risk factors for dementia and Alzheimer' s disease-findings from a community-based cohort study in Stockholm, Sweden]. , 2005, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[40]  M. Fleming,et al.  Pim-1 Ligand-bound Structures Reveal the Mechanism of Serine/Threonine Kinase Inhibition by LY294002* , 2005, Journal of Biological Chemistry.

[41]  Heinz H. Bauschke,et al.  Working memory impairment in a transgenic amyloid precursor protein TgCRND8 mouse model of Alzheimer's disease , 2005, Genes, brain, and behavior.

[42]  F. LaFerla,et al.  Alzheimer's disease: Aβ, tau and synaptic dysfunction , 2005 .

[43]  Frank M LaFerla,et al.  Alzheimer's disease: Abeta, tau and synaptic dysfunction. , 2005, Trends in molecular medicine.

[44]  N. Mizushima.  Methods for monitoring autophagy. , 2004, The international journal of biochemistry & cell biology.

[45]  James Lowe,et al.  Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders , 2003, Ageing Research Reviews.

[46]  H. Braak,et al.  Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. , 2003, The American journal of pathology.

[47]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[48]  R. Chang,et al.  Phosphorylation of eukaryotic initiation factor-2&agr; (eIF2&agr;) is associated with neuronal degeneration in Alzheimer's disease , 2002, Neuroreport.

[49]  R. Chang,et al.  Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. , 2002, Neuroreport.

[50]  W. Markesbery,et al.  Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.

[51]  D. Wolf,et al.  The Active Sites of the Eukaryotic 20 S Proteasome and Their Involvement in Subunit Precursor Processing* , 1997, The Journal of Biological Chemistry.

[52]  A. Ott.  Risk of dementia: The Rotterdam Study , 1997 .

[53]  A. Goldberg,et al.  Lactacystin and clasto-Lactacystin β-Lactone Modify Multiple Proteasome β-Subunits and Inhibit Intracellular Protein Degradation and Major Histocompatibility Complex Class I Antigen Presentation* , 1997, The Journal of Biological Chemistry.

[54]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[55]  A. Berns,et al.  Proviral tagging in E mu‐myc transgenic mice lacking the Pim‐1 proto‐oncogene leads to compensatory activation of Pim‐2. , 1995, The EMBO journal.

[56]  P. Laird,et al.  In vivo analysis of Pim-1 deficiency. , 1993, Nucleic acids research.

[57]  R. Reeves,et al.  Recombinant human pim-1 protein exhibits serine/threonine kinase activity. , 1991, The Journal of biological chemistry.

[58]  A. Berns,et al.  The pim‐1 oncogene encodes two related protein‐serine/threonine kinases by alternative initiation at AUG and CUG. , 1991, The EMBO journal.

[59]  F. Sigaux,et al.  The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[61]  Wim Quint,et al.  Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.